---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021643"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:12:28.533072+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology raises ~$50M in private placement of shares and pre-funded warrants

## Summary
- Gross proceeds of ~$50M from 8.85M shares at $4.78 and pre-funded warrants for 1.61M shares at $4.779.
- Participants include Deep Track Capital, Ridgeback Capital, Blue Owl Healthcare, Laurion Capital, and StemPoint Capital.
- Proceeds to fund development of lead ADC candidate PYX-201 for solid tumors and for working capital.
- Private placement expected to close on or about Feb 29, 2024; registration statement to be filed by Mar 27, 2024.
- Leerink Partners serving as lead placement agent; LifeSci Capital as co-placement agent.

## SEC filing metadata
- accession: 0000950170-24-021643
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/0000950170-24-021643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/pyxs-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021643
- JSON: https://secwatch.observer/filing/0000950170-24-021643.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021643.txt

## Key facts
- Material Agreements
  Pyxis Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-02-26).
  - Action: entry
  - Counterparty: the Purchasers
  - Effective: 2024-02-26
  source text: On February 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Pre-Funded Warrant Shares held by the Purchasers (the “Registrable Securities”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/0000950170-24-021643-index.htm
- Material Agreements
  Pyxis Oncology, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $50 million (effective 2024-02-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $50 million
  - Effective: 2024-02-26
  source text: On February 26, 2024, Pyxis Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/0000950170-24-021643-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.